Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?

References

• Abdelrahman, M., L. Douziech Eyrolles, S. Y. Alkarib, K. Herve-Aubert, S. Ben Djemaa, H. Marchais, I. Chourpa, and S. David. 2017. siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation. European Journal of Pharmaceutical Sciences 106:287–93. doi: 10.1016/j.ejps.2017.05.062.
   PubMed Web of Science ®Google Scholar
• Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 34 (2):154–6. doi: 10.1038/ng1161.
   PubMed Web of Science ®Google Scholar
• Ahmet, I., H. J. Tae, E. G. Lakatta, and M. Talan. 2017. Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats. Canadian Journal of Physiology and Pharmacology 95 (3):268–74. doi: 10.1139/cjpp-2016-0512.
   PubMed Web of Science ®Google Scholar
• Ahn, J., I. Cho, S. Kim, D. Kwon, and T. Ha. 2008. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. Journal of Hepatology 49 (6):1019–28. doi: 10.1016/j.jhep.2008.08.012.
   PubMed Web of Science ®Google Scholar
• Alvi, S. S., I. A. Ansari, M. K. Ahmad, J. Iqbal, and M. S. Khan. 2017. Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity. Biomedicine & Pharmacotherapy = Pharmacotherapy 96:1082–93. doi: 10.1016/j.biopha.2017.11.116.
   PubMed Web of Science ®Google Scholar
• Arnett, D. K., R. S. Blumenthal, M. A. Albert, A. B. Buroker, Z. D. Goldberger, E. J. Hahn, C. D. Himmelfarb, A. Khera, D. Lloyd-Jones, J. W. McEvoy, et al. 2019. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 74 (10):1376–1414.
   PubMed Web of Science ®Google Scholar
• Baass, A., G. Dubuc, M. Tremblay, E. E. Delvin, J. O'Loughlin, E. Levy, J. Davignon, and M. Lambert. 2009. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clinical Chemistry 55 (9):1637–45. doi: 10.1373/clinchem.2009.126987.
   PubMed Web of Science ®Google Scholar
• Banach, M., A. M. Patti, R. V. Giglio, A. F. G. Cicero, A. G. Atanasov, G. Bajraktari, E. Bruckert, O. Descamps, D. M. Djuric, M. Ezhov, et al. 2018. The Role of nutraceuticals in statin intolerant patients. Journal of the American College of Cardiology. 72 (1):96–118. doi: 10.1016/j.jacc.2018.04.040.
   PubMed Web of Science ®Google Scholar
• Barrios, V., C. Escobar, A. F. Cicero, D. Burke, P. Fasching, M. Banach, and E. Bruckert. 2017. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements 24:1–15. doi: 10.1016/j.atherosclerosissup.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Basnet, P., and N. Skalko-Basnet. 2011. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16 (6):4567–98. doi: 10.3390/molecules16064567.
   PubMed Web of Science ®Google Scholar
• Bays, H. E., A. P. Tighe, R. Sadovsky, and M. H. Davidson. 2008. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Review of Cardiovascular Therapy 6 (3):391–409. doi: 10.1586/14779072.6.3.391.
   PubMedGoogle Scholar
• Berglund, L., J. D. Brunzell, A. C. Goldberg, I. J. Goldberg, F. Sacks, M. H. Murad, and A. F. Stalenhoef. 2012. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 97 (9):2969–89. doi: 10.1210/jc.2011-3213.
   PubMed Web of Science ®Google Scholar
• Bhatt, D. L., P. G. Steg, M. Miller, E. A. Brinton, T. A. Jacobson, S. B. Ketchum, R. T. Doyle, Jr., R. A. Juliano, L. Jiao, C. Granowitz, et al. 2019. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine 380 (1):11–22. doi: 10.1056/NEJMoa1812792.
   PubMed Web of Science ®Google Scholar
• Bradberry, J. C., and D. E. Hilleman. 2013. Overview of omega-3 fatty acid therapies. P & T: A Peer-Reviewed Journal for Formulary Management 38 (11):681–91.
   PubMedGoogle Scholar
• Brenjian, S., A. Moini, N. Yamini, L. Kashani, M. Faridmojtahedi, M. Bahramrezaie, M. Khodarahmian, and F. Amidi. 2020. Resveratrol treatment in patients with polycystic ovary syndrome decreased pro-inflammatory and endoplasmic reticulum stress markers. American Journal of Reproductive Immunology 83 (1):e13186. doi: 10.1111/aji.13186.
   PubMed Web of Science ®Google Scholar
• Brown, M. S., and J. L. Goldstein. 1997. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (3):331–40. doi: 10.1016/S0092-8674(00)80213-5.
   PubMed Web of Science ®Google Scholar
• Bursill, C. A., and P. D. Roach. 2006. Modulation of cholesterol metabolism by the green tea polyphenol (-)-epigallocatechin gallate in cultured human liver (HepG2) cells. Journal of Agricultural and Food Chemistry 54 (5):1621–6. doi: 10.1021/jf051736o.
   PubMed Web of Science ®Google Scholar
• Cai, Y., D. Lu, Y. Zou, C. Zhou, H. Liu, C. Tu, F. Li, L. Liu, and S. Zhang. 2017. Curcumin protects against intestinal origin endotoxemia in rat liver cirrhosis by targeting PCSK9. Journal of Food Science 82 (3):772–80. doi: 10.1111/1750-3841.13647.
   PubMed Web of Science ®Google Scholar
• Cameron, J., T. Ranheim, M. A. Kulseth, T. P. Leren, and K. E. Berge. 2008. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201 (2):266–73. doi: 10.1016/j.atherosclerosis.2008.02.004.
   PubMed Web of Science ®Google Scholar
• Canuel, M., X. Sun, M. C. Asselin, E. Paramithiotis, A. Prat, and N. G. Seidah. 2013. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PloS One 8 (5):e64145. doi: 10.1371/journal.pone.0064145.
   PubMed Web of Science ®Google Scholar
• Cao, A., M. Wu, H. Li, and J. Liu. 2011. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. Journal of Lipid Research 52 (3):518–30. doi: 10.1194/jlr.M010603.
   PubMed Web of Science ®Google Scholar
• Cao, M. M., X. Lu, G. D. Liu, Y. Su, Y. B. Li, and J. Zhou. 2018. Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1. Experimental and Therapeutic Medicine 15 (1):576–84. doi: 10.3892/etm.2017.5400.
   PubMed Web of Science ®Google Scholar
• Catapano, A. L., I. Graham, G. De Backer, O. Wiklund, M. J. Chapman, H. Drexel, A. W. Hoes, C. S. Jennings, U. Landmesser, T. R. Pedersen, et al. 2016. 2016 ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal 37 (39):2999–3058. doi: 10.1093/eurheartj/ehw272.
   PubMed Web of Science ®Google Scholar
• Cicero, A. F. G., A. Colletti, G. Bajraktari, O. Descamps, D. M. Djuric, M. Ezhov, Z. Fras, N. Katsiki, M. Langlois, G. Latkovskis, et al. 2017. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Nutrition Reviews 75 (9):731–67. doi: 10.1093/nutrit/nux047.
   PubMed Web of Science ®Google Scholar
• Cui, C. J., S. Li, C. G. Zhu, J. Sun, Y. Du, Y. Zhang, N. Q. Wu, Y. L. Guo, R. X. Xu, Y. Gao, et al. 2016. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1alpha pathway in HepG2 cells. Journal of Cellular and Molecular Medicine 20 (12):2374–83. doi: 10.1111/jcmm.12931.
   PubMed Web of Science ®Google Scholar
• De Castro-Orós, I., R. Solà, R. M. Valls, A. Brea, P. Mozas, J. Puzo, and M. Pocoví. 2016. Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of armolipid plus with berberine. PloS One 11 (3):e0150785. doi: 10.1371/journal.pone.0150785.
   PubMed Web of Science ®Google Scholar
• Demers, A., S. Samami, B. Lauzier, C. Des Rosiers, E. T. Ngo Sock, H. Ong, and G. Mayer. 2015. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (12):2517–25. doi: 10.1161/ATVBAHA.115.306032.
   PubMed Web of Science ®Google Scholar
• Denis, M., J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, C. Lazure, N. G. Seidah, and A. Prat. 2012. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 125 (7):894–901. doi: 10.1161/CIRCULATIONAHA.111.057406.
   PubMed Web of Science ®Google Scholar
• Ding, Z., S. Liu, X. Wang, X. Deng, Y. Fan, C. Sun, Y. Wang, and J. L. Mehta. 2015. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxidants & Redox Signaling 22 (9):760–71. doi: 10.1089/ars.2014.6054.
   PubMed Web of Science ®Google Scholar
• Dong, B., H. Li, A. B. Singh, A. Cao, and J. Liu. 2015. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. Journal of Biological Chemistry 290 (7):4047–58. doi: 10.1074/jbc.M114.597229.
   PubMed Web of Science ®Google Scholar
• Dong, B., M. Wu, H. Li, F. B. Kraemer, K. Adeli, N. G. Seidah, S. W. Park, and J. Liu. 2010. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. Journal of Lipid Research 51 (6):1486–95. doi: 10.1194/jlr.M003566.
   PubMed Web of Science ®Google Scholar
• Dong, S., S. Zhang, Z. Chen, R. Zhang, L. Tian, L. Cheng, F. Shang, and J. Sun. 2018. Berberine could ameliorate cardiac dysfunction via interfering myocardial lipidomic profiles in the rat model of diabetic cardiomyopathy. Frontiers in Physiology 9:1042. doi: 10.3389/fphys.2018.01042.
   PubMed Web of Science ®Google Scholar
• Dou, X., C. Fan, L. Wo, J. Yan, Y. Qian, and X. Wo. 2008. Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells. Planta Medica 74 (11):1374–9. doi: 10.1055/s-2008-1081316.
   PubMed Web of Science ®Google Scholar
• Dwivedi, D. J., P. M. Grin, M. Khan, A. Prat, J. Zhou, A. E. Fox-Robichaud, N. G. Seidah, and P. C. Liaw. 2016. Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis. Shock (Augusta, GA) 46 (6):672–80. doi: 10.1097/SHK.0000000000000682.
   PubMed Web of Science ®Google Scholar
• Fahey, J. W., and K. K. Stephenson. 2002. Pinostrobin from honey and Thai ginger (Boesenbergia pandurata): A potent flavonoid inducer of mammalian phase 2 chemoprotective and antioxidant enzymes. Journal of Agricultural and Food Chemistry 50 (25):7472–6. doi: 10.1021/jf025692k.
   PubMed Web of Science ®Google Scholar
• Feingold, K. R., A. H. Moser, J. K. Shigenaga, S. M. Patzek, and C. Grunfeld. 2008. Inflammation stimulates the expression of PCSK9. Biochemical and Biophysical Research Communications 374 (2):341–4. doi: 10.1016/j.bbrc.2008.07.023.
   PubMed Web of Science ®Google Scholar
• Ferri, N., G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, and A. L. Catapano. 2012. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 220 (2):381–6. doi: 10.1016/j.atherosclerosis.2011.11.026.
   PubMed Web of Science ®Google Scholar
• Gao, W. Y., P. Y. Chen, S. F. Chen, and M. J. Wu. 2018. Pinostrobin inhibits proprotein convertase subtilisin/kexin-type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells. Journal of Agricultural and Food Chemistry 66 (24):6083–93. doi: 10.1021/acs.jafc.8b02559.
   PubMed Web of Science ®Google Scholar
• Giunzioni, I., H. Tavori, R. Covarrubias, A. S. Major, L. Ding, Y. Zhang, R. M. DeVay, L. Hong, D. Fan, I. M. Predazzi, et al. 2016. Local effects of human PCSK9 on the atherosclerotic lesion. The Journal of Pathology 238 (1):52–62. doi: 10.1002/path.4630.
   PubMed Web of Science ®Google Scholar
• Gonnelli, S., C. Caffarelli, K. Stolakis, C. Cuda, N. Giordano, and R. Nuti. 2015. Efficacy and tolerability of a nutraceutical combination (Red Yeast Rice, Policosanols, and Berberine) in patients with low-moderate risk hypercholesterolemia: A double-blind, placebo-controlled study. Current Therapeutic Research 77:1–6. doi: 10.1016/j.curtheres.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Goto, T., Y. Saito, K. Morikawa, Y. Kanamaru, and S. Nagaoka. 2012. Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. British Journal of Nutrition 107 (6):769–73. doi: 10.1017/S0007114511003758.
   PubMed Web of Science ®Google Scholar
• Graversen, C. B., S. Lundbye-Christensen, B. Thomsen, J. H. Christensen, and E. B. Schmidt. 2016. Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study. Vascular Pharmacology 76:37–41. doi: 10.1016/j.vph.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2):227–39. doi: 10.1161/01.CIR.0000133317.49796.0E.
   PubMed Web of Science ®Google Scholar
• Gu, C., L. Fu, X. Yuan, and Z. Liu. 2017. Promoting effect of pinostrobin on the proliferation, differentiation, and mineralization of murine pre-osteoblastic MC3T3-E1 cells. Molecules (Basel, Switzerland) 22 (10): E1735. doi: 10.3390/molecules22101735.
   PubMed Web of Science ®Google Scholar
• Hampton, E. N., M. W. Knuth, J. Li, J. L. Harris, S. A. Lesley, and G. Spraggon. 2007. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proceedings of the National Academy of Sciences of Sciences 104 (37):14604–9. doi: 10.1073/pnas.0703402104.
   PubMed Web of Science ®Google Scholar
• He, Z., Y. Peng, W. Duan, Y. Tian, J. Zhang, T. Hu, Y. Cai, Y. Feng, and G. Li. 2015. Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. The Journal of Toxicological Sciences 40 (1):127–36. doi: 10.2131/jts.40.127.
   PubMed Web of Science ®Google Scholar
• Hooper, A. J., A. D. Marais, D. M. Tanyanyiwa, and J. R. Burnett. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193 (2):445–8. doi: 10.1016/j.atherosclerosis.2006.08.039.
   PubMed Web of Science ®Google Scholar
• Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 109 (9):1125–31. doi: 10.1172/JCI0215593.
   PubMed Web of Science ®Google Scholar
• Imai, K., and K. Nakachi. 1995. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ (Clinical Research Ed.) 310 (6981):693–6. doi: 10.1136/bmj.310.6981.693.
   PubMedGoogle Scholar
• Jain, A. P., K. K. Aggarwal, and P. Y. Zhang. 2015. Omega-3 fatty acids and cardiovascular disease. European Review for Medical and Pharmacological Sciences 19 (3):441–5.
   PubMed Web of Science ®Google Scholar
• Jeong, H. J., H. S. Lee, K. S. Kim, Y. K. Kim, D. Yoon, and S. W. Park. 2008. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. Journal of Lipid Research 49 (2):399–409. doi: 10.1194/jlr.M700443-JLR200.
   PubMed Web of Science ®Google Scholar
• Jing, Y., T. Hu, C. Lin, Q. Xiong, F. Liu, J. Yuan, X. Zhao, and R. Wang. 2019. Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor alpha-mediated pathway in L02cells. European Journal of Pharmacology 855:216–26. doi: 10.1016/j.ejphar.2019.05.019.
   PubMed Web of Science ®Google Scholar
• Jump, D. B. 2008. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Current Opinion in Lipidology 19 (3):242–7. doi: 10.1097/MOL.0b013e3282ffaf6a.
   PubMed Web of Science ®Google Scholar
• Kang, Q., and A. Chen. 2009a. Curcumin inhibits srebp-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 150 (12):5384–94. doi: 10.1210/en.2009-0517.
   PubMed Web of Science ®Google Scholar
• Kang, Q., and A. Chen. 2009b. Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. British Journal of Pharmacology 157 (8):1354–67. doi: 10.1111/j.1476-5381.2009.00261.x.
   PubMed Web of Science ®Google Scholar
• Khoo, H. E., K. N. Prasad, K. W. Kong, Y. Jiang, and A. Ismail. 2011. Carotenoids and their isomers: Color pigments in fruits and vegetables. Molecules (Basel, Switzerland) 16 (2):1710–38. doi: 10.3390/molecules16021710.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. Journal of Lipid Research 45 (7):1169–96. doi: 10.1194/jlr.R300019-JLR200.
   PubMed Web of Science ®Google Scholar
• Kim, K. M., H. O. Pae, M. Zhung, H. Y. Ha, Y. A. Ha, K. Y. Chai, Y. K. Cheong, J. M. Kim, and H. T. Chung. 2008. Involvement of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory inducible nitric oxide synthase in RAW264.7 macrophages. Biomedicine & Pharmacotherapy = Pharmacotherapy 62 (9):630–6. doi: 10.1016/j.biopha.2008.01.008.
   PubMed Web of Science ®Google Scholar
• Kitamura, K.,. Y. Okada, K. Okada, Y. Kawaguchi, and S. Nagaoka. 2017. Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells. Molecular Nutrition & Food Research 61 (8). doi: 10.1002/mnfr.201600836.
   Web of Science ®Google Scholar
• Kong, W., J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, et al. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 10 (12):1344–51. doi: 10.1038/nm1135.
   PubMed Web of Science ®Google Scholar
• Kono, S., K. Shinchi, K. Wakabayashi, S. Honjo, I. Todoroki, Y. Sakurai, K. Imanishi, H. Nishikawa, S. Ogawa, and M. Katsurada. 1996. Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. Journal of Epidemiology 6 (3):128–33. doi: 10.2188/jea.6.128.
   PubMedGoogle Scholar
• Kourimate, S., C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zaïr, P. Nguyen, M. Krempf, B. Cariou, and P. Costet. 2008. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. Journal of Biological Chemistry 283 (15):9666–73. doi: 10.1074/jbc.M705831200.
   PubMed Web of Science ®Google Scholar
• Kuhnast, S., J. W. van der Hoorn, E. J. Pieterman, A. M. van den Hoek, W. J. Sasiela, V. Gusarova, A. Peyman, H. L. Schafer, U. Schwahn, J. W. Jukema, et al. 2014. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. Journal of Lipid Research 55 (10):2103–12. doi: 10.1194/jlr.M051326.
   PubMed Web of Science ®Google Scholar
• Kysenius, K.,. P. Muggalla, K. Matlik, U. Arumae, and H. J. Huttunen. 2012. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cellular and Molecular Life Sciences 69 (11):1903–16. doi: 10.1007/s00018-012-0977-6.
   PubMed Web of Science ®Google Scholar
• Labonte, P., S. Begley, C. Guevin, M. C. Asselin, N. Nassoury, G. Mayer, A. Prat, and N. G. Seidah. 2009. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology (Baltimore, MD) 50 (1):17–24. doi: 10.1002/hep.22911.
   PubMed Web of Science ®Google Scholar
• Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. Journal of Clinical Investigation 116 (11):2995–3005. doi: 10.1172/JCI29383.
   PubMed Web of Science ®Google Scholar
• Lambert, G., A.-L. Jarnoux, T. Pineau, O. Pape, M. Chetiveaux, C. Laboisse, M. Krempf, and P. Costet. 2006. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147 (10):4985–95. doi: 10.1210/en.2006-0098.
   PubMed Web of Science ®Google Scholar
• Lee, M. S., J. Y. Park, H. Freake, I. S. Kwun, and Y. Kim. 2008. Green tea catechin enhances cholesterol 7alpha-hydroxylase gene expression in HepG2 cells. British Journal of Nutrition 99 (6):1182–5. doi: 10.1017/S0007114507864816.
   PubMed Web of Science ®Google Scholar
• Levy, E., A. Ben Djoudi Ouadda, S. Spahis, A. T. Sane, C. Garofalo, E. Grenier, L. Emonnot, S. Yara, P. Couture, J. F. Beaulieu, et al. 2013. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 227 (2):297–306. doi: 10.1016/j.atherosclerosis.2013.01.023.
   PubMed Web of Science ®Google Scholar
• Li, H., B. Dong, S. W. Park, H. S. Lee, W. Chen, and J. Liu. 2009. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. Journal of Biological Chemistry 284 (42):28885–95. doi: 10.1074/jbc.M109.052407.
   PubMed Web of Science ®Google Scholar
• Li, S., Y. L. Guo, R. X. Xu, Y. Zhang, C. G. Zhu, J. Sun, P. Qing, N. Q. Wu, L. X. Jiang, and J. J. Li. 2014. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 234 (2):441–5. doi: 10.1016/j.atherosclerosis.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Liu, D. L., L. J. Xu, H. Dong, G. Chen, Z. Y. Huang, X. Zou, K. F. Wang, Y. H. Luo, and F. E. Lu. 2015. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chinese Journal of Integrative Medicine 21 (2):132–8. doi: 10.1007/s11655-014-1775-1.
   PubMed Web of Science ®Google Scholar
• Massaro, M.,. E. Scoditti, M. A. Carluccio, M. C. Campana, and R. De Caterina. 2010. Omega-3 fatty acids, inflammation and angiogenesis: Basic mechanisms behind the cardioprotective effects of fish and fish oils. Cellular and Molecular Biology (Noisy-le-Grand, France) 56 (1):59–82.
   PubMed Web of Science ®Google Scholar
• Mbikay, M.,. F. Sirois, C. Gyamera-Acheampong, G. S. Wang, P. Rippstein, A. Chen, J. Mayne, F. W. Scott, and M. Chretien. 2015. Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6. Journal of Diabetes 7 (1):74–84. doi: 10.1111/1753-0407.12139.
   PubMed Web of Science ®Google Scholar
• Meister, G., and T. Tuschl. 2004. Mechanisms of gene silencing by double-stranded RNA. Nature 431 (7006):343–9. doi: 10.1038/nature02873.
   PubMed Web of Science ®Google Scholar
• Melone, M.,. L. Wilsie, O. Palyha, A. Strack, and S. Rashid. 2012. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. Journal of the American College of Cardiology 59 (19):1697–705. doi: 10.1016/j.jacc.2011.11.064.
   PubMed Web of Science ®Google Scholar
• Memon, R. A., I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2000. Infection and inflammation induce LDL oxidation in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 20 (6):1536–42. doi: 10.1161/01.ATV.20.6.1536.
   PubMed Web of Science ®Google Scholar
• Muramatsu, K., M. Fukuyo, and Y. Hara. 1986. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. Journal of Nutritional Science and Vitaminology 32 (6):613–22. doi: 10.3177/jnsv.32.613.
   PubMed Web of Science ®Google Scholar
• Nwachukwu, J. C., S. Srinivasan, N. E. Bruno, A. A. Parent, T. S. Hughes, J. A. Pollock, O. Gjyshi, V. Cavett, J. Nowak, R. D. Garcia-Ordonez, et al. 2014. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. eLife 3:e02057. doi: 10.7554/eLife.02057.
   PubMed Web of Science ®Google Scholar
• Ochin, C. C., and M. Garelnabi. 2018. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells. Cardiovascular & Hematological Disorders-Drug Targets 18 (1):61–70. doi: 10.2174/1871529X18666180201130340.
   PubMedGoogle Scholar
• Ogura, M. 2018. PCSK9 inhibition in the management of familial hypercholesterolemia. Journal of Cardiology 71 (1):1–7. doi: 10.1016/j.jjcc.2017.07.002.
   PubMed Web of Science ®Google Scholar
• Olszanecki, R., J. Jawień, M. Gajda, L. Mateuszuk, A. Gebska, M. Korabiowska, S. Chłopicki, and R. Korbut. 2005. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. Journal of Physiology and Pharmacology 56 (4):627–35.
   PubMed Web of Science ®Google Scholar
• Orsu, P., B. V. Murthy, and A. Akula. 2013. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. Journal of Neural Transmission 120 (8):1217–23. doi: 10.1007/s00702-013-0982-4.
   PubMed Web of Science ®Google Scholar
• Parker, H. M., N. A. Johnson, C. A. Burdon, J. S. Cohn, H. T. O’Connor, and J. George. 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology 56 (4):944–51. doi: 10.1016/j.jhep.2011.08.018.
   PubMed Web of Science ®Google Scholar
• Patel, N. K., G. Jaiswal, and K. K. Bhutani. 2016. A review on biological sources, chemistry and pharmacological activities of pinostrobin. Natural Product Research 30 (18):2017–27. doi: 10.1080/14786419.2015.1107556.
   PubMed Web of Science ®Google Scholar
• Pecin, I., M. L. Hartgers, G. K. Hovingh, R. Dent, and Z. Reiner. 2017. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology 24 (13):1383–401. doi: 10.1177/2047487317717346.
   PubMed Web of Science ®Google Scholar
• Poirier, S., G. Mayer, S. Benjannet, E. Bergeron, J. Marcinkiewicz, N. Nassoury, H. Mayer, J. Nimpf, A. Prat, and N. G. Seidah. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. Journal of Biological Chemistry 283 (4):2363–72. doi: 10.1074/jbc.M708098200.
   PubMed Web of Science ®Google Scholar
• Quiles, J. L., M. D. Mesa, C. L. Ramírez-Tortosa, C. M. Aguilera, M. Battino, A. ́ Gil, and M. C. Ramírez-Tortosa, 2002. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology 22 (7):1225–31. doi: 10.1161/01.ATV.0000020676.11586.F2.
   PubMed Web of Science ®Google Scholar
• Ramirez-Bosca, A., A. Soler, M. A. Carrion, J. Diaz-Alperi, A. Bernd, C. Quintanilla, E. Quintanilla Almagro, and J. Miquel. 2000. An hydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mechanisms of Ageing and Development 119 (1-2):41–7. doi: 10.1016/S0047-6374(00)00169-X.
   PubMed Web of Science ®Google Scholar
• Ramirez-Tortosa, M. C., M. D. Mesa, M. C. Aguilera, J. L. Quiles, L. Baro, C. L. Ramirez-Tortosa, E. Martinez-Victoria, and A. Gil. 1999. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147 (2):371–8. doi: 10.1016/S0021-9150(99)00207-5.
   PubMed Web of Science ®Google Scholar
• Ranheim, T., M. Mattingsdal, J. M. Lindvall, O. L. Holla, K. E. Berge, M. A. Kulseth, and T. P. Leren. 2008. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. Journal of Cellular Physiology 217 (2):459–67. doi: 10.1002/jcp.21519.
   PubMed Web of Science ®Google Scholar
• Reiner, Z. 2014. Resistance and intolerance to statins. Nutrition, Metabolism & Cardiovascular Diseases 24 (10):1057–66. doi: 10.1016/j.numecd.2014.05.009.
   PubMed Web of Science ®Google Scholar
• Reiner, Z. 2015. PCSK9 inhibitors–past, present and future. Expert Opinion on Drug Metabolism & Toxicology 11 (10):1517–21. doi: 10.1517/17425255.2015.1075506.
   PubMed Web of Science ®Google Scholar
• Reiner, Z. 2019. The association between lipid-lowering drugs and circulating concentration of PCSK9. European Journal of Preventive Cardiology 26 (9):928–9. doi: 10.1177/2047487319840179.
   PubMed Web of Science ®Google Scholar
• Reiner, Z., U. Laufs, F. Cosentino, and U. Landmesser. 2019. The year in cardiology 2018: Prevention. European Heart Journal 40 (4):336–44. doi: 10.1093/eurheartj/ehy894.
   PubMed Web of Science ®Google Scholar
• Riccioni, G., B. Mancini, E. Di Ilio, T. Bucciarelli, and N. D'Orazio. 2008. Protective effect of lycopene in cardiovascular disease. European Review for Medical and Pharmacological Sciences 12 (3):183–90.
   PubMed Web of Science ®Google Scholar
• Ried, K., and P. Fakler. 2011. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas 68 (4):299–310. doi: 10.1016/j.maturitas.2010.11.018.
   PubMed Web of Science ®Google Scholar
• Roubtsova, A., M. N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, C. Lazure, K. Cianflone, N. G. Seidah, and A. Prat. 2011. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arteriosclerosis, Thrombosis, and Vascular Biology 31 (4):785–91. doi: 10.1161/ATVBAHA.110.220988.
   PubMed Web of Science ®Google Scholar
• Ruscica, M., C. Ricci, C. Macchi, P. Magni, R. Cristofani, J. Liu, A. Corsini, and N. Ferri. 2016. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. Journal of Biological Chemistry 291 (7):3508–19. doi: 10.1074/jbc.M115.664706.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A., M. C. Serban, A. Gluba-Brzozka, D. P. Mikhailidis, A. F. Cicero, J. Rysz, and M. Banach. 2016. Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition 32 (11-12):1179–92. doi: 10.1016/j.nut.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Seidah, N. G., Z. Awan, M. Chretien, and M. Mbikay. 2014. PCSK9: A key modulator of cardiovascular health. Circulation Research 114 (6):1022–36. doi: 10.1161/CIRCRESAHA.114.301621.
   PubMed Web of Science ®Google Scholar
• Shearer, G. C., O. V. Savinova, and W. S. Harris. 2012. Fish oil – How does it reduce plasma triglycerides? Biochimica et biophysica Acta 1821 (5):843–51. doi: 10.1016/j.bbalip.2011.10.011.
   PubMed Web of Science ®Google Scholar
• Simic, I., and Z. Reiner. 2015. Adverse effects of statins – Myths and reality. Current Pharmaceutical Design 21 (9):1220–6. doi: 10.2174/1381612820666141013134447.
   PubMed Web of Science ®Google Scholar
• Singh, D. K., L. Li, and T. D. Porter. 2006. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. Journal of Pharmacology and Experimental Therapeutics 318 (3):1020–6. doi: 10.1124/jpet.106.107144.
   PubMed Web of Science ®Google Scholar
• Soni, K. B., and R. Kuttan. 1992. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian Journal of Physiology and Pharmacology 36 (4):273–5.
   PubMedGoogle Scholar
• Sorokin, A. V., Z. H. Yang, B. L. Vaisman, S. Thacker, Z. X. Yu, M. Sampson, C. N. Serhan, and A. T. Remaley. 2016. Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. The Journal of Nutritional Biochemistry 35:58–65. doi: 10.1016/j.jnutbio.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Spigoni, V., R. Aldigeri, M. Antonini, M. M. Micheli, F. Fantuzzi, A. Fratter, M. Pellizzato, E. Derlindati, I. Zavaroni, R. C. Bonadonna, et al. 2017. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: Results from a randomized, double blind, placebo-controlled study. International Journal of Molecular Sciences 18 (7):1498. doi: 10.3390/ijms18071498.
   PubMed Web of Science ®Google Scholar
• Srivastava, R., M. Dikshit, R. C. Srimal, and B. N. Dhawan. 1985. Anti-thrombotic effect of curcumin. Thrombosis Research 40 (3):413–7. doi: 10.1016/0049-3848(85)90276-2.
   PubMed Web of Science ®Google Scholar
• Sultan Alvi, S., I. A. Ansari, I. Khan, J. Iqbal, and M. S. Khan. 2017. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia. Free Radical Biology and Medicine 108:394–403. doi: 10.1016/j.freeradbiomed.2017.04.012.
   PubMed Web of Science ®Google Scholar
• Sun, H. L., Y. R. Wu, F. F. Song, J. Gan, L. Y. Huang, L. Zhang, and C. Huang. 2018. Role of PCSK9 in the development of mouse periodontitis before and after treatment: A double-edged sword. The Journal of Infectious Diseases 217 (4):667–80. doi: 10.1093/infdis/jix574.
   PubMed Web of Science ®Google Scholar
• Tai, M. H., P. K. Chen, P. Y. Chen, M. J. Wu, C. T. Ho, and J. H. Yen. 2014. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Molecular Nutrition & Food Research 58 (11):2133–45. doi: 10.1002/mnfr.201400366.
   PubMed Web of Science ®Google Scholar
• Tang, Z., L. Jiang, J. Peng, Z. Ren, D. Wei, C. Wu, L. Pan, Z. Jiang, and L. Liu. 2012. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. International Journal of Molecular Medicine 30 (4):931–8. doi: 10.3892/ijmm.2012.1072.
   PubMed Web of Science ®Google Scholar
• Tang, Z. H., J. Peng, Z. Ren, J. Yang, T. T. Li, T. H. Li, Z. Wang, D. H. Wei, L. S. Liu, X. L. Zheng, et al. 2017. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway. Atherosclerosis 262:113–22. doi: 10.1016/j.atherosclerosis.2017.04.023.
   PubMed Web of Science ®Google Scholar
• Tome-Carneiro, J., M. Larrosa, A. Gonzalez-Sarrias, F. A. Tomas-Barberan, M. T. Garcia-Conesa, and J. C. Espin. 2013. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Current Pharmaceutical Design 19 (34):6064–93. doi: 10.2174/13816128113199990407.
   PubMed Web of Science ®Google Scholar
• Topchiy, E., M. Cirstea, H. J. Kong, J. H. Boyd, Y. Wang, J. A. Russell, and K. R. Walley. 2016. Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor. PloS One 11 (5):e0155030. doi: 10.1371/journal.pone.0155030.
   PubMed Web of Science ®Google Scholar
• Wiciński, M., J. Żak, B. Malinowski, G. Popek, and G. Grześk. 2017. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA Journal 8 (4):391–402. doi: 10.1007/s13167-017-0106-6.
   PubMed Web of Science ®Google Scholar
• Wu, C. Y., Z. H. Tang, L. Jiang, X. F. Li, Z. S. Jiang, and L. S. Liu. 2012. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Molecular and Cellular Biochemistry 359 (1-2):347–58. doi: 10.1007/s11010-011-1028-6.
   PubMed Web of Science ®Google Scholar
• Wu, N., K. Fu, Y. J. Fu, Y. G. Zu, F. R. Chang, Y. H. Chen, X. L. Liu, Y. Kong, W. Liu, and C. B. Gu. 2009. Antioxidant activities of extracts and main components of Pigeonpea [Cajanus cajan (L.) Millsp.] leaves. Molecules (Basel, Switzerland) 14 (3):1032–43. doi: 10.3390/molecules14031032.
   PubMed Web of Science ®Google Scholar
• Xian, Y. F., S. P. Ip, Z. X. Lin, Q. Q. Mao, Z. R. Su, and X. P. Lai. 2012. Protective effects of pinostrobin on beta-amyloid-induced neurotoxicity in PC12 cells. Cellular and Molecular Neurobiology 32 (8):1223–30. doi: 10.1007/s10571-012-9847-x.
   PubMed Web of Science ®Google Scholar
• Xiao, H. B., Z. L. Sun, H. B. Zhang, and D. S. Zhang. 2012. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacological Reports 64 (4):889–95. doi: 10.1016/S1734-1140(12)70883-6.
   PubMed Web of Science ®Google Scholar
• Yang, C. S., and J. M. Landau. 2000. Effects of tea consumption on nutrition and health. The Journal of Nutrition 130 (10):2409–12. doi: 10.1093/jn/130.10.2409.
   PubMed Web of Science ®Google Scholar
• Yang, X., J. Zhang, L. Chen, Q. Wu, and C. Yu. 2018. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells. Experimental Cell Research 366 (2):152–60. doi: 10.1016/j.yexcr.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Yuan, F., H. Wang, Y. Tian, Q. Li, L. He, N. Li, and Z. Liu. 2016. Fish oil alleviated high-fat diet–induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: A transcriptomic study. Lipids in Health and Disease 15 (1):1. doi: 10.1186/s12944-016-0190-y.
   PubMedGoogle Scholar